Stay updated on Trametinib and Pembrolizumab in NSCLC Clinical Trial
Sign up to get notified when there's something new on the Trametinib and Pembrolizumab in NSCLC Clinical Trial page.

Latest updates to the Trametinib and Pembrolizumab in NSCLC Clinical Trial page
- Check6 days agoNo Change Detected
- Check13 days agoChange DetectedThe page revision tag was updated from v3.5.3 to v3.5.4, indicating a minor update to the page's metadata.SummaryDifference0.1%

- Check20 days agoNo Change Detected
- Check35 days agoChange DetectedThe page’s revision/version label was updated from v3.5.2 to v3.5.3, indicating a non-clinical site/software update.SummaryDifference0.1%

- Check42 days agoChange DetectedRevision: v3.5.2 replaces the previous v3.5.0.SummaryDifference0.1%

- Check71 days agoChange DetectedRevision updated from v3.4.3 to v3.5.0 on the page.SummaryDifference0.1%

- Check78 days agoChange DetectedThe page header now shows Revision: v3.4.3, replacing the previous Revision: v3.4.2.SummaryDifference0.1%

- Check107 days agoChange DetectedThis update shows a minor revision label change from v3.4.1 to v3.4.2. No substantive changes to the study details or eligibility criteria appear to have occurred.SummaryDifference0.1%

Stay in the know with updates to Trametinib and Pembrolizumab in NSCLC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Trametinib and Pembrolizumab in NSCLC Clinical Trial page.